Covaxin shows 81% viability; here's how it piles facing Covishield

Covaxin shows 81% viability; here’s how it piles facing Covishield

Bharat Biotech, on March 3, said its antibody was 81% successful in forestalling COVID-19 after the third round of clinical preliminaries. India has affirmed two antibodies—Covaxin created by Hyderabad-based Bharat Biotech and Covishield from the Oxford-AstraZeneca stable being fabricated by Serum Institute of India (SII) — for crisis use in the country. Bharat Biotech, on […]